Anti-PD-1 Therapy Response Predicted by the Combination of Exosomal PD-L1 and CD28

Anti-PD-1 therapy has been approved for cancer treatment. However, the response rate is unsatisfactory. The expression of PD-L1 in tumor tissues is unreliable to predict the treatment response. Recent studies have suggested that exosomal PD-L1 not only exerts immunosuppressive effects but also plays...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chaoxu, Fan, Yibo, Che, Xiaofang, Zhang, Min, Li, Zhi, Li, Ce, Wang, Shuo, Wen, Ti, Hou, Kezuo, Shao, Xinye, Liu, Yunpeng, Qu, Xiujuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266952/
https://www.ncbi.nlm.nih.gov/pubmed/32528882
http://dx.doi.org/10.3389/fonc.2020.00760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266952/
https://www.ncbi.nlm.nih.gov/pubmed/32528882
http://dx.doi.org/10.3389/fonc.2020.00760

Ejemplares similares